Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease

We present a case of refractory ileocolonic Crohn's disease in a 27-year-old female treated with dual ustekinumab and vedolizumab biologic therapy. She had mucosal healing for the first time in 13 years after a 10-month treatment of ustekinumab overlapped with 6 months of vedolizumab. No side e...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Eddie Y., Loomes, Dustin E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698793/
https://www.ncbi.nlm.nih.gov/pubmed/29250117
http://dx.doi.org/10.1155/2017/5264216
_version_ 1783280828705406976
author Liu, Eddie Y.
Loomes, Dustin E.
author_facet Liu, Eddie Y.
Loomes, Dustin E.
author_sort Liu, Eddie Y.
collection PubMed
description We present a case of refractory ileocolonic Crohn's disease in a 27-year-old female treated with dual ustekinumab and vedolizumab biologic therapy. She had mucosal healing for the first time in 13 years after a 10-month treatment of ustekinumab overlapped with 6 months of vedolizumab. No side effects were observed during the 6 months of dual biologic therapy. Short-term dual biologic therapy may be considered as a treatment option for induction of remission in refractory cases of Crohn's disease.
format Online
Article
Text
id pubmed-5698793
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-56987932017-12-17 Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease Liu, Eddie Y. Loomes, Dustin E. Case Rep Med Case Report We present a case of refractory ileocolonic Crohn's disease in a 27-year-old female treated with dual ustekinumab and vedolizumab biologic therapy. She had mucosal healing for the first time in 13 years after a 10-month treatment of ustekinumab overlapped with 6 months of vedolizumab. No side effects were observed during the 6 months of dual biologic therapy. Short-term dual biologic therapy may be considered as a treatment option for induction of remission in refractory cases of Crohn's disease. Hindawi 2017 2017-11-08 /pmc/articles/PMC5698793/ /pubmed/29250117 http://dx.doi.org/10.1155/2017/5264216 Text en Copyright © 2017 Eddie Y. Liu and Dustin E. Loomes. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Liu, Eddie Y.
Loomes, Dustin E.
Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
title Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
title_full Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
title_fullStr Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
title_full_unstemmed Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
title_short Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
title_sort ustekinumab and vedolizumab dual biologic therapy in the treatment of crohn's disease
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698793/
https://www.ncbi.nlm.nih.gov/pubmed/29250117
http://dx.doi.org/10.1155/2017/5264216
work_keys_str_mv AT liueddiey ustekinumabandvedolizumabdualbiologictherapyinthetreatmentofcrohnsdisease
AT loomesdustine ustekinumabandvedolizumabdualbiologictherapyinthetreatmentofcrohnsdisease

Ejemplares similares